Longeveron (LGVN) EPS (Basic) Growth (1y) (2021 - 2026)
Longeveron (LGVN) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -16.29% |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -58,379.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.67% |
| Mar 31, 2026 | 48.51% |
| Dec 31, 2025 | 28.57% |
| Sep 30, 2025 | -17.25% |
| Jun 30, 2025 | 99.98% |
| Mar 31, 2025 | 99.97% |
| Dec 31, 2024 | 99.98% |
| Sep 30, 2024 | 99.99% |
| Jun 30, 2024 | 31.42% |
| Mar 31, 2024 | 91.55% |
| Dec 31, 2023 | -30.48% |
| Sep 30, 2023 | -11.64% |
| Jun 30, 2023 | -13.53% |
| Mar 31, 2023 | -936.80% |
| Dec 31, 2022 | -108.95% |
| Sep 30, 2022 | 79.16% |
| Jun 30, 2022 | 77.73% |
| Mar 31, 2022 | -17,507.56% |
| Dec 31, 2021 | 2,776.80% |
| Sep 30, 2021 | -1,879.53% |